United States: Physician-Owned Distributor (POD) Update

For some time, we have been reporting on issues involving federal government scrutiny of physician-owned distributors ("PODs"). From the Department of Health and Human Services Office of Inspector General's ("OIG") issuance of the March 2013 OIG Special Fraud Alert ("Special Fraud Alert"), to the Reliance Medical Systems challenge to the Fraud Alert, to the subsequent failure of that challenge, to further OIG scrutiny of the connections between PODs and physician-owned hospitals – the controversy over PODs has continued seemingly unabated.

Continuing our coverage of this important issue, we now report that, following up on a November 2015 Senate Finance Committee ("Committee") hearing ("November 2015 Hearing"), the Committee this month issued a comprehensive report entitled Physician Owned Distributorships: An Update on Key Issues and Areas of Congressional Concern ("Report"). In short, the Committee continues to be highly critical of the entire POD industry and its surgeon participants, and it urges not only expanded regulation in this area, but also increased and expanded investigative and enforcement activity by OIG and DOJ.

Summary of Report

The Report begins by identifying the key federal laws at issue in assessing the appropriateness of PODs – the Anti-Kickback Statute ("AKS"), the Physician Self-Referral Law ("Stark Law"), and the Physician Payments Sunshine Act ("Sunshine Act") – and outlining a timeline and summary of its extensive POD-related investigative activities, starting in February 2011. The Committee's scrutiny of this issue has spanned five years, including the release of a report outlining issues with PODs in June 2011 ("June 2011 Report") and, most recently, the November 2015 Hearing. If anything, the Committee's overall findings and conclusions on PODs have become more scathing.

The Report traces other federal activity with respect to PODs, including publication of the OIG's Special Fraud Alert, the 2014 publication of physician payment data as mandated by the Sunshine Act, and the issuance of other subsequent OIG publications. In addition, the Report considers in some detail the 2014-15 criminal indictment and arrest of Dr. Aria Sabit, a POD spine surgeon who practiced in California and Michigan, and his association with Reliance Medical Systems – as noted, the subject of DOJ investigative activity. While the criminal cases against Dr. Sabit are still pending, the Report cites facts acknowledged by Dr. Sabit as to how POD relationships caused him to compromise his medical judgment: in short, "incentivized by this illegal kickback arrangement and his involvement in the conspiracy, [Dr. Sabit] performed medically unnecessary surgeries that caused serious bodily injury [to patients]."1

Citing additional investigative efforts against surgeons launched by DOJ in November 2015, the Report states that the "Committee staff fully supports DOJ efforts to prosecute surgeons who put patients at risk for personal financial gain. We believe that DOJ's continued focus on these arrangements could persuade POD surgeons to sever their relationships with PODs and remind the health care industry that the POD business structure results in behavior that is unethical and potentially illegal."

Interestingly, the Committee undertook its own statistical analysis of POD utilization rates, employing data compiled by CBS News. While acknowledging that its analysis is "somewhat rudimentary," the Committee concludes in Section V of the Report that, based on this data and other sources, POD surgeons saw "significantly more" patients than non-POD surgeons, and performed fusion surgery on nearly twice as many patients as non-POD surgeons.

The Committee also traced changes in the POD business landscape since the OIG's 2013 issuance of the Special Fraud Alert. Its findings include:

  • POD growth has slowed but expansion has continued, with PODs now in 43 states and D.C.
  • Widespread POD penetration has distorted pricing, because of "predatory pricing" activity by POD physicians2
  • PODs have been able to circumvent required Open Payments/Sunshine reporting of physician owner payments by converting those surgeon owners to employees, for whom reporting is not required, or directing payments to family members or friends, or even outsourcing payments to a third party who then pays the surgeon
  • Although some PODs have implemented policies in an attempt to mitigate risks inherent to the business model, hospitals that do business with PODs still face "serious risks" that can only be eliminated by not conducting business with PODs. Despite the fact that hospitals are implementing policies to manage relationships with PODs, some hospitals experience "intense pressure" from PODs to allow them to remain hospital suppliers.

In Section VII of the Report, the Committee discusses how six named hospital systems have sought to limit or ban PODs, with some encountering extensive physician pushback. At the same time, the Committee acknowledges that some physician-owned businesses are not problematic, and that "physician ownership in legitimate innovator companies is allowable."3

The Report concludes in Section VIII that "the Committee remains highly concerned about the damage that PODs have done, and are continuing to do, to patient safety and federal healthcare programs." It includes the following five sweeping findings and detailed recommendations:

  • There is a lack of transparency in physician ownership of PODs. The Report recommends expanding Open Payments/Sunshine reporting requirements, and requiring hospitals and ambulatory surgical centers to review – and document their review of – such reported data. It further urges CMS and OIG to expand its compliance guidance to recommend hospital restrictions on PODs.
  • When hospitals purchase products from PODs, overutilization results, in turn suggesting that "some of the surgeries performed are medically unnecessary or overly complex." The Committee recommends that GAO "examine the costs and benefits of CMS requiring hospitals that choose to purchase from PODs to perform enhanced quality assurance and utilization review activities in connection with surgeries using POD-supplied products."
  • The business structure and payments involved with PODs have been found illegal. Moreover, according to the Report, "overt or implied threats made by physicians to move their practice unless a hospital accepts their POD would likely violate fraud and abuse laws." The Committee recommends continued and expanded efforts by law enforcement to prosecute physicians, PODs, and hospitals that are violating the law.
  • PODs are migrating from large hospitals and hospital systems that have implemented policies regulating their relationships with PODs, to smaller hospitals that do not have these policies. The Committee recommends that CMS not only require hospitals to establish policies governing their relationships with PODs consistent with OIG guidance, but also that CMS withhold reimbursement for surgeries involving POD-supplied devices, until those hospitals have implemented POD policies.
  • Changes in the payment structures of PODs are an "attempt to circumvent the AKS and the Sunshine Act." The Committee makes multiple recommendations to address this finding, including increased CMS enforcement actions "to ensure compliance with Sunshine Act reporting requirements," additional CMS guidance or rulemaking relating to Sunshine Act reporting requirements, and potential updates to the OIG Special Fraud Alert, including OIG consideration of whether the list of suspect POD characteristics in the Special Fraud Alert should be "revised or expanded."

Key Take-Aways

Based on the history of governmental scrutiny of PODs, our key take-aways from the Report include:

  • Hospital providers must remain vigilant in considering physician ownership of all types of distributors – not just in the spinal device sphere. The Report – as with much of the guidance and enforcement to date – has been focused on PODs in the field of spinal surgery, but the Committee acknowledges that its conclusions about PODs are not limited to the spinal device POD market. While current federal scrutiny remains on the spinal device market, this does not rule out enforcement action in other areas. Thus, it is important for hospital providers to be vigilant about monitoring physician ownership of all types of distributors.
  • At the same time, hospitals should ensure that their policies seeking to limit improper POD arrangements do not unwittingly address legitimate industry relationships with physicians. As the Reports notes, not all relationships between industry and physicians are improper. Both drug and device manufacturers rely extensively on physician expertise in research and other consulting relationships. Further, many device manufacturers have modest intellectual property (e.g., royalty) arrangements with physician innovators, that typically – and appropriately – exclude royalties to those innovators for their own self-referrals. We have reviewed some hospital anti-POD policies that are so broadly worded as to forbid even these legitimate arrangements.
  • Anticipate further guidance from OIG. As noted in the Report, after the Committee released its June 2011 report, it asked OIG to consider whether existing guidance was sufficient to address the increase in PODs. At that time, OIG questioned whether additional guidance was necessary. Nevertheless, since then, the OIG has issued a Special Fraud Alert (March 2013), a report on spinal device PODs (October 2013), and a report on the overlap between PODs and physician-owned hospitals (August 2015). Given the Committee's ongoing attention to this matter and recent DOJ enforcement actions, the time is ripe for additional compliance and related guidance from OIG.
  • Expect further development of data points relating to PODs. The data cited in the Report is limited and sometimes anecdotal. Although that nature of the POD business model may make it difficult to collect and analyze statistically rigorous data about the impact of the proliferation of PODs, we expect the government to continue to use Sunshine Act data to glean as much information as possible on the continuing area of interest.
  • Be on the lookout for stronger Sunshine Act provisions. The Report raises the possibility that the Sunshine Act could be strengthened on multiple fronts, including Congressional consideration of statutory increases in penalties for intentional Sunshine Act violations, additional CMS regulations expanding reporting requirements, and more vigorous OIG enforcement.


The Report in no uncertain terms warns of future oversight in this area, given the "significant concern for numerous members of the Committee staff, including the Chairman." Stay tuned for our ongoing coverage.


1. Notably, Kevin Reynolds, the son of one of Dr. Sabit's patients (now deceased), testified at the November 2015 Hearing. In his written testimony (available here), Mr. Reynolds blames Dr. Sabit's interest in Apex Medical Technologies LLC – an interest about which Mr. Reynolds and his mother were not aware prior to the surgery – for Dr. Sabit's decision to perform a more complex spinal fusion surgery than the surgery to which the patient agreed. Mr. Reynolds states, "I believe that Dr. Sabit had a clear financial incentive to use more screws and rods in my mother's back surgery. And I believe that this financial incentive played a role in his decision to perform more complex surgery on her that was not medically necessary."

2. According to hearing testimony by one physician in November, POD physicians who are able to supplement their income via POD self-referrals are able to sign contracts with insurers for "ridiculously low" reimbursement amounts, in turn enabling them to shut non-POD physicians out of the market.

3. In a footnote to the Report, the Committee cites approvingly "manufacturers who may have a relatively small portion of physician ownership (examples include physician ownership as a result of an initial capital investment, or development of new or innovative intellectual property) which generally diminishes as the company's products gain market acceptance. Unlike PODs, these companies widely market and sell their products to healthcare facilities where their physician owners do not practice, and in addition, physician owners' revenue is not tied to their referrals or usage of the company's devices.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions